NervGen Pharma (NGEN)
NASDAQ:NGEN
Want to see NGEN full AI Analyst Report?
NGEN Stock Chart & Stats
$4.07
$0.00(0.00%)
At close: 4:00 PM EST
$4.07
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.50 - $6.30
Previous CloseN/A
VolumeN/A
Average Volume (3M)135.64K
Market Cap
$168.34M
Enterprise Value$396.61M
Total Cash (Recent Filing)$11.40M
Total Debt (Recent Filing)$33.23K
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Aug 12, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding80,930,870
10 Day Avg. Volume172,718
30 Day Avg. Volume135,636
Financial Highlights & Ratios
PEG Ratio1.67
Price to Book (P/B)82.04
Price to Sales (P/S)0.00
P/FCF Ratio-12.55
Enterprise Value/Market Cap2.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.48K
Enterprise Value/Ebitda-15.60
Forecast
1Y Price Target
$11.90Price Target Upside192.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biological Mechanism EvidenceElectrophysiological data showing reductions in abnormal hyperactive reticulospinal signaling in limbs provide objective support for the proposed biological mechanism of functional recovery.
Durable Functional ImprovementsLonger-term follow-up demonstrated durable and strengthening improvements in hand function and overall motor assessments after treatment cessation, indicating potential for sustained patient benefit.
Trial EnrollmentA multicenter trial design that does not require patient relocation, combined with high unmet need in spinal cord injury, should support stronger patient enrollment and reduce recruitment hurdles.
Bears Say
Funding ShortfallCurrent cash resources are likely insufficient to fully fund a pivotal trial launch and are expected to require additional capital raises that could dilute shareholders.
Regulatory UncertaintyLimited precedent for pivotal trial designs in this indication creates uncertainty about regulatory alignment and keeps development risk elevated.
NervGen Pharma News
NGEN FAQ
What was NervGen Pharma’s price range in the past 12 months?
NervGen Pharma lowest stock price was $1.50 and its highest was $6.30 in the past 12 months.
What is NervGen Pharma’s market cap?
NervGen Pharma’s market cap is $168.34M.
When is NervGen Pharma’s upcoming earnings report date?
NervGen Pharma’s upcoming earnings report date is Aug 12, 2026 which is in 79 days.
How were NervGen Pharma’s earnings last quarter?
Currently, no data Available
Is NervGen Pharma overvalued?
According to Wall Street analysts NervGen Pharma’s price is currently Undervalued.
Does NervGen Pharma pay dividends?
NervGen Pharma does not currently pay dividends.
What is NervGen Pharma’s EPS estimate?
NervGen Pharma’s EPS estimate is -0.08.
How many shares outstanding does NervGen Pharma have?
NervGen Pharma has 80,930,870 shares outstanding.
What happened to NervGen Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NervGen Pharma?
Currently, no hedge funds are holding shares in NGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NervGen Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.90 (192.38% Upside)
$11.90 (192.38% Upside)
Insider Transactions
Sold Shares
Worth $261.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.45%
12-Months-Change
Fundamentals
Return on Equity
-9999.00%
Trailing 12-Months
Asset Growth
35.21%
Trailing 12-Months
Company Description
NervGen Pharma
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.
NGEN Stock 12 Month Forecast
Average Price Target
$11.90
▲(192.38% Upside)
Technical Analysis
―
Bright Minds Biosciences
―
MYND Life Sciences
―
Mindbio Therapeutics Corp.
―
Neural Therapeutics Inc.
―
Ownership Overview
19.50% Insiders
0.66% Other Institutional Investors
79.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---